ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VPHM Viropharma Incorporated (MM)

49.98
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Viropharma Incorporated (MM) NASDAQ:VPHM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 49.98 0 01:00:00

ViroPharma To Release 2013 Third Quarter Financial Results On October 31, 2013

28/10/2013 4:00pm

PR Newswire (US)


Viropharma Incorporated (MM) (NASDAQ:VPHM)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Viropharma Incorporated (MM) Charts.

EXTON, Pa., Oct. 28, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2013 are expected to be released on Thursday, October 31, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2013 third quarter financial results along with other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until November 15, 2013.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Copyright 2013 PR Newswire

1 Year Viropharma Incorporated (MM) Chart

1 Year Viropharma Incorporated (MM) Chart

1 Month Viropharma Incorporated (MM) Chart

1 Month Viropharma Incorporated (MM) Chart

Your Recent History

Delayed Upgrade Clock